Market Newsdesk

• Detailed
  M
  apping
  and Sampling Program Completed
• Drill
  T
  argets
  S
  elected
  at Sandra Prospect
• 1,500
  m
  Self
  –
  Funded
  Drill Program
  Scheduled for Q1 2021
  

VANCOUVER, British Columbia, Nov. 25, 2020 (GLOBE NEWSWIRE) — Mirasol Resources Ltd. (TSX-V: MRZ) (OTCPK: MRZLF) (the “Company” or “Mirasol”) is pleased to report on the first systematic exploration at its district-scale Inca Gold precious metals project (“Inca Gold”), located in northern Chile. A recently completed surface survey at the promising Sandra prospect confirmed the presence of a Au/Ag Intermediate Sulphidation Epithermal (“ISE”) system. Based on results, a 1,500m diamond drill program is planned to commence in Q1 2021.

Mirasol’s Chair and Interim CEO, Patrick Evans, stated: “The areal extent of the Sandra vein field is impressive. Results to date demonstrate potential with anomalous Au and Ag values returned over a strike length of more than 1.2 km. Further detailed surface sampling, mapping and drilling will give us a complete understanding of the full potential of this prospect.”

The 16,300 ha Inca Gold project is located in Region III of Chile, approximately 100 km north of Copiapo, and within the Inca Del Oro mining district that hosts both Santiago Metals Delirio Cu/Au mine and PanAust/Codelco’s Inca de Oro Cu/Au porphyry deposit. Inca Gold lies between 2,000 to 3,000m ASL and has good access allowing for year-round exploration. Mirasol’s initial exploration at the Sandra prospect has defined five Au/Ag prospects, none of which have been drill tested. Mirasol has also staked 2,400 ha of exploration claims directly to the south of the Sandra target and plans to complete a first pass evaluation of these new claims during the current field campaign.

Figure 1: Inca Gold – Location Map

Exploration Program

Mirasol’s first surface work program, which commenced this season, has to date focused exclusively on the Sandra prospect, and was designed to evaluate the extensive Au/Ag vein system hosted in a Paleocene caldera setting where ISE mineralization was previously recognized. At least five subparallel vein trends striking northwest, within a 2.5 x 4 km area, have been mapped. Continuous individual vein trends extend over strike lengths of 1.2 km and are up to 3m wide.

Mirasol initial surveys included 1:2,000 scale geological mapping of the quartz vein swarms, systematic rock sawn geochemical channel sampling across the key veins and reconnaissance geochemical rock chip sampling over outlying areas of the prospect. In total, 498 samples were collected from 138 individual sawn channel cuts. Seven zones of veining and anomalous geochemistry have been outlined within the Sandra prospect, and three of these targets have been prioritized for testing by an initial 1,500m drill program.

Figure 2: Sandra Prospect – Geology, Structure and Drill Targets

Mapping and detailed channel sampling have revealed brecciated and crustiform-colloform banding with common bladed and replacement vein textures. Multiple pulses of vein fill are observed, with an initial pulse of milky quartz with lattice bladed and drusy textures carrying anomalous Au (0.1 to 0.42 g/t) and Ag (24 to 168 g/t). A later pulse, characterized by massive and crustiform quartz, also carries elevated Au geochemistry (0.13 to 0.26 g/t) and Cu (473 to 6,950 ppm), with Cu oxides and chalcopyrite. Higher Pb and Zn values are also associated with this later pulse that is generally emplaced along re-opened margins of the veins at the contact with host rocks.

Target	Channel	From (m)	To (m)	Width (m)	Ag ( g/t )	Au ( g/t )	AgEq ( g/t )	Cu (ppm)	Pb (ppm)	Zn (ppm)
Veta Valle	IG-CH-021	1.90	2.26	0.36	156	0.43	192	1,145	2,410	1,380
Veta Valle	IG-CH-022	0.00	0.31	0.31	86	0.07	92	1,685	2,150	568
Veta Escuela	IG-CH-002	1.53	1.78	0.25	66	0.13	77	4,930	2,370	113,500
Veta Escuela W	IG-CH-016	0.53	0.80	0.27	64	0.07	70	499	159	84
Lomo Ballena	IG-CH-071	0.00	0.29	0.29	58	0.03	61	6,950	18,600	10,250
Veta Escuela	IG-CH-001	1.69	1.94	0.25	47	0.16	61	3,660	3,510	94,800
Lomo Ballena	IG-CH-066	0.47	1.07	0.60	50	0.05	54	1,656	5,760	988
Veta Valle	IG-CH-013	0.00	0.76	0.76	34	0.16	48	6,080	1,050	700
Lomo Ballena	IG-CH-070	0.29	0.93	0.64	29	0.03	32	785	10,520	2,010
Lomo Ballena	IG-CH-065	0.28	0.69	0.41	19	0.04	22	755	3,480	278
Table: Selected Geochemical Assay Results from the Rock Sawn Channel Sampling Program (using a 20 g/t AgEq1 cut off)

Historical sampling by Newmont and due diligence sampling by Mirasol returned encouraging Au and Ag grades from selective sampling along the various vein structures (see news release January 13, 2020).   This more selective sampling, although not representative in nature, confirms the presence of higher grade pulses in the system that could be related to possible “leakage” during repetitive reactivation and subsequent sealing of the mineralized structures. The recent systematic sampling has revealed details of favourable vein textures and geochemistry which may provide vectors to potentially higher grade and completely preserved mineralized shoots at depth. Planned drill hole locations have been based on structural information collected from detailed mapping along the trend, as well as geochemical Ag and Au data. To date, the widths of most of the higher-grade mineralized pulses are sub-one meter at surface.

Detailed geochemical analysis of the channel sample database has also shown a notable increase in precious metals grades and other pathfinder elements, which are vectoring to an elevation below 2,450m ASL, indicating that this elevation may represent a more favorable part of the hydrothermal system. The presence of boiling textures in outcrop (lattice blading and platy carbonate; as voids and pseudo-morphed by quartz), and anomalous trace element geochemistry (Zn, Pb, Sb, Te, Se and Bi) is also supporting the potential presence of an ISE-style Au and Ag mineralized zone below surface.

_______________
¹ Silver equivalent (“AgEq”) is calculated using the 3-year average metal prices of US$ 1457/oz for Au and US$ 17.18/oz for Ag. Recoveries are assumed to be 100% as no metallurgical test data is available. The equation used is thus:
AgEq g/t = Ag g/t + (Au g/t x 84.81)

Drill Targeting Overview

The 1,500m diamond drilling program, planned for Q1 2021, will target three of the most prospective zones along the principal Sandra trend, and initially test to a depth of 80 to 200m vertically below the outcropping surface exposures. These targets include Lomo Ballena (“LB”), Veta Escuela (“VE”) and Veta Valle (“VV”). The three targets, which represent the deepest eroded parts of the outcropping system (<2,450m ASL), show an overall increase in Au and Ag grades when compared with the higher elevation surrounding areas, and are considered geologically, structurally and geochemically strong targets for this initial drill program.

Figure 3: Inca Gold – Planned Drill Targets and AgEq Geochemical Results

The LB vein exposure is located along the 2,450m ASL elevation contour and sits on an important intersection of north-west and north-northwest trending structures. Cumulative vein, veinlets and stockwork reach up to 15m in width, with individual vein exposures of over 3m wide.

The VE vein is exposed at an elevation 30m lower and to the northwest of the LB vein. This outcropping exposure has some of the best epithermal textures and shows clear evidence of the multi-pulse character of the local system, coincident with strong geochemical anomalies in Au and Ag.

Finally, the VV vein forms the northwestern extension of the VE vein and is exposed by deeper erosion in the valley. This outcrop is the lowest topographically exposed vein structure along the main Sandra trend, with topography increasing to the northwest. This section of the trend hosts one of the highest assay results recovered in channel sampling to date, with an intersection of 0.36m returning grades of 0.43 g/t Au and 156 g/t Ag.

Five diamond drill holes, ranging from 90 to 200m, have been selected as initial priorities. Based on results, an additional series of drill holes are planned to follow along strike, down-dip and to step out to other prospective epithermal structures in the system. Results will be reported when they are available.

About Mirasol Resources Ltd

Mirasol is a well-funded exploration company focused in Chile and Argentina. Mirasol has six partner-funded projects, two with Newcrest Mining Ltd (Chile), and one each with First Quantum Minerals (Chile), Mine Discovery Fund (Chile), Mineria Activa (Chile) and Silver Sands Resources (Argentina). Mirasol is currently self-funding exploration at two projects, Inca Gold (Chile) and Sacha Marcelina (Argentina).

For further information, contact:

Patrick Evans, Chair and Interim CEO
or
Jonathan Rosset, VP Corporate Development

Tel: +1 (604) 602-9989
Email: [email protected]
Website: www.mirasolresources.com

Qualified Person Statement: Mirasol’s disclosure of technical and scientific information in this press release has been reviewed and approved by Chris Ford, CEng FIMMM, a senior consultant for the Company, who serves as a Qualified Person under the definition of National Instrument 43-101.

QAQC: Mirasol applies industry standard exploration sampling methodologies and techniques. All geochemical rock and drill samples are collected under the supervision of the company’s geologists in accordance with industry practice. Geochemical assays are obtained and reported under a quality assurance and quality control (QA/QC) program. Samples are dispatched to an ISO 9001:2008 accredited laboratory in Chile for analysis. Assay results from channel, trench, and drill core samples may be higher, lower or similar to results obtained from surface samples due to surficial oxidation and enrichment processes or due to natural geological grade variations in the primary mineralization.

Forward Looking Statements: The information in this news release contains forward looking statements that are subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in our forward-looking statements. Factors that could cause such differences include: changes in world commodity markets, equity markets, costs and supply of materials relevant to the mining industry, change in government and changes to regulations affecting the mining industry and to policies linked to pandemics, social and environmental related matters. Forward-looking statements in this release include statements regarding future exploration programs, operation plans, geological interpretations, mineral tenure issues and mineral recovery processes. Although we believe the expectations reflected in our forward-looking statements are reasonable, results may vary, and we cannot guarantee future results, levels of activity, performance or achievements. Mirasol disclaims any obligations to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as may be required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Shares Issued and Outstanding:
54,156,043

(Expressed in United States dollars except where otherwise indicated)

MONTREAL, Nov. 25, 2020 (GLOBE NEWSWIRE) — (TSXV: GMN) GobiMin Inc. (“GobiMin” or the “Company”, together with its subsidiaries collectively the “Group”) reports its financial and operating results for the third quarter of 2020. The unaudited condensed interim financial statements along with quarterly highlights of management’s discussion and analysis have been filed with SEDAR (www.sedar.com) and are also available at the website of the Company (www.gobimin.com).

Financial Highlights

	3 months ended September 30		12 months ended
	2020	2019	December 31, 2019
	$	$	$
Revenue	0.3 million	0.4 million	1.3 million
Gain on disposal of financial assets	0.1 million	0.5 million	0.6 million
Fair value gain on financial assets	55,000	25,000	0.9 million
Net (loss)/profit for the period/year	(0.4 million)	46,000	(0.5 million)
(Loss)/Profit attributable to shareholders of the Company	(0.2 million)	0.1 million	(0.3 million)
(LBITDA)/EBITDA (1)	(0.3 million)	11,000	(0.6 million)
Basic and diluted (loss)/earnings per share	(0.005)	0.001	(0.007)
(LBITDA)/EBITDA per share (1)	(0.006)	0.0002	(0.013)
Cash and cash equivalents	18.3 million	21.4 million	17.8 million
Cash and cash equivalents per share (1)	0.37	0.43	0.36
Working capital	21.5 million	23.8 million	21.3 million
Total current liabilities	2.4 million	2.3 million	2.5 million
Total non-current financial liabilities	–	0.4 million	0.4 million
Total assets	74.5 million	76.0 million	76.0 million

Note:

(1) As non-IFRS measurements, (LBITDA)/EBITDA ((loss)/earnings before interest income and expense, income taxes, depreciation and amortisation), (LBITDA)/EBITDA per share and Cash and cash equivalents per share do not comply with IFRS and, therefore, the amounts presented in the above table may not be comparable to similar data presented by other companies. The data is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

Business Summary and Development

1. 
   COVID-19 Pandemic Impacts

   
   During the reporting period under review, the COVID-19 pandemic is raising uncertainty about the global supply chains and how quickly things will return to normal. Although data indicated that the global economy should produce a rebound in the third quarter and poised to begin a recovery, the latest lockdowns showed that the recovery was slowing markedly, which could exacerbate medium-term economic scarring. To date there have been significant wide-spread stock market fluctuations.

   The Company has been monitoring the potential impact of COVID-19 pandemic on our operations since mid-February 2020. COVID-19 is threatening the supply chains and logistics setup of the Group, thus causing unprecedented impact on our normal business activities. The Group’s operations may be adversely affected by unstable employment if great portions of our workforce, especially technical workers, are confined to their homes by government order or cannot return to workplace by restrictions on travel. As at September 30, 2020, the management had assessed the credit risk of the loan receivable and the fair market value of the investment properties with reference to the recent market prices for similar properties in the same locations and similar conditions. Based on the assessment, an impairment loss of $0.2 million on investment properties located in China was recognized during the period. Save for this, the management determined that its general operation of business working capital and the value of the Company’s assets were not materially impacted. A realistic view of mastering the crisis is keeping healthy cash position and implementing cautious cash management. Thus, we have developed treasury strategies including but not limited to suspension of dividend distribution, strengthening cost control measures and salary reduction programme. Meanwhile, the Company continues to work on timely adjustment on investment plans in light of the current conditions and will explore opportunities in a proactive manner.

   As uncertainties from the outbreak are likely to persist, the management will actively seek out the most up-to-date market information and formulate various plans for each scenario in the context of business continuity.

2. 
   Gold Project in Xinjiang

   
   The Company owns a 70% equity interest in Xinjiang Tongyuan Minerals Limited which holds the Sawayaerdun Gold Project (the “Gold Project”) in Xinjiang. The exploration licence has an expiry date on August 22, 2021. The mining licence was expired on December 23, 2019 and renewal application had been accepted by the related departments. Due to the outbreak of COVID-19 in Xinjiang in July 2020, approval process of mining licence renewal by the Department of Land and Resources was further impacted. Comments on the land rehabilitation report has been received from the Department of Land and Resources of Xinjiang in November 2020 and the revised report will be submitted by the end of 2020. It is expected that our renewal application will be processed after determination of reserve by the Department of Land and Resources as well as payment for the related fee based on the assessed reserve. However, due to work piled up during the lockdown, it may take longer time to proceed our application.

   The on-site industrial test on applying bio-tech methodology on extraction of metals from large-scale samples of gold ores was in pre-oxidation stage. Attributable to the two waves of COVID-19 in Xinjiang in July and October 2020, the test has been adversely affected by the lockdown and travel restrictions. Suspension of public services of the local government from July to September 2020 delayed the approval process for our sulfuric acid procurement application. In virtue of the acid shortage, we adjusted the spray time and suspend the spray of oxidized ores to ensure pre-oxidation of the ore heap. Alkali tablets cannot be transported to the test site on time due to lockdown measures, resulting in the delay of neutralization work to the next spring. In consideration of the long delivery time of samples to the Institute in Beijing, we engaged a local analysis centre to conduct sample analysis work. According to their analysis results, iron and arsenic in the ore heap has been gradually separated out. More samples were delivered for comprehensive analysis to the Institute in October. We will have a better knowledge of the development and effect of the pre-oxidation test after receiving the results.

   For the period ended September 30, 2020, there was addition of $0.1 million in the exploration and evaluation assets and the Group had a contractual commitment of $1.6 million for the future development of the Gold Project.

3. 
   Financial Assets

   (i) Listed Securities

   As at September 30, 2020, the fair value of listed securities held by the Group amounted to $0.2 million (December 31, 2019: $0.1 million) which mainly included $0.1 million (December 31, 2019: $11,000) investment in listed stock, futures and options trading through registered brokerage firms in Hong Kong and $0.1 million (December 31, 2019: $0.1 million) for a stock listed in Canada. For the nine months ended September 30, 2020, the gain on disposal of listed securities amounted to $0.2 million (Q3 2019: $0.5 million) and fair value loss was $0.1 million (Q3 2019: gain of $0.9 million).

   (ii) Unlisted Investments

   The Group holds 670,000 shares of Dragon Silver Holdings Limited (“Dragon Silver”) representing 9.90% of its total issued capital at an investment cost of $1.1 million (HK$8,710,000). Dragon Silver is a Hong Kong based company mainly engaged in trading, production, processing and investment in precious metals and non-ferrous metals and related products.

   Pursuant to the subscription agreement dated December 29, 2017, the guarantor of the agreement irrevocably guaranteed to the Group that the amount of dividends declared and paid by Dragon Silver during each of the financial years ending from June 30, 2018 to 2022 shall not be less than $0.16 (HK$1.25) per share (“Dividend Guarantee”). If the dividend per share declared and paid by Dragon Silver is less than the Dividend Guarantee, the guarantor shall compensate the Group the sum being calculated as the shortfall (“Dividend Compensation Amount”). As at September 30, 2020, Dragon Silver has not declared and paid any dividend to the Group. In October 2020, the guarantor paid to the Group the Dividend Compensation Amount for the financial year ended 30 June 2020 of $0.1 million. The carrying value of the investment together with the Dividend Guarantee, the related profit guarantee and put option as at September 30, 2020 was $1.4 million (December 31, 2019: $1.4 million).

   As at September 30, 2020, other unlisted investments held by the Group amounted to $0.2 million (December 31, 2019: $0.2 million). During the period under review, the fair value gain on other unlisted investments was $10,000 (Q3 2019: $1,000).

   (iii) Debentures and Certificate of Deposit

   The Group would hold debentures and certificate of deposit bearing low risks and reasonable interest return from various industries through the open market. Debentures are held to receive coupon interest payments as well as to realize potential gains. The Group may dispose of debentures through the open market when the Group requires funds for operational or other investment needs.

   As at September 30, 2020, the Group held debentures of $3.1 million (December 31, 2019: $4.6 million) with coupon rates ranged from 4.250% to 7.375% (December 31, 2019: 4.250% to 7.750%) per annum and maturities ranged between November 4, 2020 and perpetual (December 31, 2019: January 17, 2020 and perpetual).

   For the nine months ended September 30, 2020, the interest income on debentures and certificate of deposit was $0.1 million (2019 Q3: $0.1 million) and fair value loss was $0.1 million (2019 Q3: gain of $0.2 million) respectively.

4. 
   Investment Properties

   
   As at September 30, 2020, the investment properties in China with carrying amount of $4.4 million was higher than the estimated fair value of $4.2 million and therefore an impairment loss on investment properties of $0.2 million was recognized for the period ended September 30, 2020 (2019: nil) and certain investment properties in Xinjiang remained vacant.

5. 
   Liquidity and Capital Resources

   
   As at September 30, 2020, working capital of the Group amounted to about $21.5 million (December 31, 2019: $21.3 million), by netting off its current assets of $23.9 million (December 31, 2019: $23.8 million) with current liabilities of $2.4 million (December 31, 2019: $2.5 million).

   Taking into account of its financial position, the management of the Group considered that its cash and cash equivalents will be more than sufficient to finance its operation, including the contractual commitments of the Gold Project of approximately $1.6 million.

For further information, please contact:

Felipe Tan, Chief Executive Officer
Tel: (852) 3586-6500
Email: [email protected]

Certain statements contained in this press release constitute forward-looking information. Such statements are based on the current expectations of management of GobiMin. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected in the forward-looking information. Forward looking information includes without limitation, statements regarding the size and quality of the Company’s mineral resources, progress in development of mineral properties, the prospective mineralization of the properties, and planned exploration programs. The reader should not place undue reliance on the forward-looking information included in this press release given that (i) actual results could differ materially from a conclusion, forecast or projection in the forward-looking information, and (ii) certain material factors or assumptions were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information could prove to be inaccurate. These statements speak only as of the date they are made, and GobiMin assumes no obligation to revise such statements as a result of any event, circumstance or otherwise, except in accordance with law.

“
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
”

To receive GobiMin press releases by email, send a message to


[email protected]


and

specify “GobiMin press releases” on the subject line

To

unsubscribe

GobiMin press releases, please send a message to



[email protected]

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Piper Sandler 32^nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 at 2:00 p.m. ET.

A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

About Agios

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company’s website at www.agios.com.

Contacts

Investors:

Holly Manning, 617-844-6630
Director, Investor Relations
[email protected]

Media:

Jessica Rennekamp, 857-209-3286
Associate Director, Corporate Communications
[email protected]

WATERTOWN, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will present at the Evercore ISI 3rd Annual HealthCONx on Thursday, December 3, 2020 at 8:25 a.m. ET.

A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.

About C4 Therapeutics

C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.

Investor & Media Contact:
Kendra Adams
SVP, Communications & Investor Relations
[email protected]

CRL
does
not cite need for additional clinical studies

CRL focuses on
drug
CMC
and device
biocompatibility
information

Conference Call Scheduled for
Today at 9:00a
.
m
.
ET

RESEARCH TRIANGLE PARK, N.C., Nov. 25, 2020 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation (NASDAQ: LQDA), today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the company’s New Drug Application (NDA) for LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH).

In the CRL, the FDA stated that it is unable to approve the NDA at this time. The CRL identified the need for additional information and clarification on chemistry, manufacturing and controls (CMC) data pertaining to the drug product and device biocompatibility. Liquidia does not believe that the items raised in the CRL will be a barrier to the ultimate approval of LIQ861.

The FDA also reconfirmed the need to conduct on-site pre-approval inspections (PAIs) of two of Liquidia’s U.S. manufacturing facilities before the application can be approved. The FDA noted it had been unable to conduct these inspections during the initial review cycle due to COVID-19 related travel restrictions.

The CRL did not cite the need to conduct further clinical studies, nor did the FDA require additional studies related to toxicology or clinical pharmacology. Of note, Liquidia believes that it can address the items raised in the CRL without delaying the otherwise projected launch timing of LIQ861 in the second half of 2022, subject to FDA approval.

“We remain very confident in LIQ861 and are committed to working closely with the FDA to address these items to support its approval,” said Neal Fowler, Chief Executive Officer at Liquidia. “With more than 70 patients now having received LIQ861 for more than two years in our clinical trials, Liquidia remains committed to PAH patients who we believe are underserved with currently available treatment options.”

Webcast and Conference Call

Liquidia will host a webcast and conference call Wednesday, November 25, 2020 at 9:00 a.m. ET to discuss this regulatory update for LIQ861. The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 3295968. A live and archived webcast of the call will also be available on the Events & Presentations page of the Liquidia website.

About LIQ861

LIQ861 is an investigational inhaled dry powder formulation of treprostinil designed using Liquidia’s PRINT^® technology with the goal of enhancing deep-lung delivery using a convenient, palm-sized dry powder inhaler (“DPI”) for the treatment of pulmonary arterial hypertension (PAH). PRINT^® technology enables development of drug particles that are precise and uniform in size, shape, weight and composition that are engineered for optimal deposition in the lung following oral inhalation. Liquidia believes LIQ861 can overcome the limitations of current inhaled therapies and has the potential to maximize the therapeutic benefits of treprostinil in treating PAH by safely delivering higher doses into the lungs. Liquidia has completed an open-label, multi-center phase 3 clinical study of LIQ861 in patients diagnosed with PAH known as INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil.

About PAH

PAH is a chronic, progressive disease caused by the hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death. Treprostinil is a synthetic analog of prostacyclin, a vasoactive mediator essential to normal lung function that is deficient in patients with PAH. PAH is a rare disease, with an estimated prevalence in the United States of approximately 30,000 patients. The exact cause of PAH is often unknown and, although the symptoms are treatable, there is no known cure for the disease.

About Liquidia

Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation, is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT^® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related anticipated submission contents and timelines, including potential resubmission of the NDA following our receipt of a CRL in November 2020, the potential for eventual FDA approval of the NDA for LIQ861, the timeline or outcome related to our patent litigation pending in the U.S. District Court for the District of Delaware or its inter partes review with the Patent Trial and Appeal Board (PTAB), the issuance of patents by the U.S. Patent and Trademark Office (USPTO) and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in Liquidia’s filings with the SEC, including the impact of the coronavirus (COVID-19) outbreak on our company and our financial condition and results of operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Media:
Michael Parks
Corporate Communications
484.356.7105
[email protected]

Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
[email protected]

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020.

TTI-622:
Poster
Presentation, Publication N
umber 1191

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Presenter: Krish Patel, M.D., Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster I
Date: Saturday, December 5, 2020; available from 10:00AM EST

TTI-621:
Oral
Presentation
,
Publication
N
umber
646

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Presenter: Steven M. Horwitz, M.D., Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Immunotherapy in T/NK Cell Lymphoma
Date: Monday, December 7, 2020; Presentation at 3:00PM EST

The presentations will be available in the Events & Presentations section of Trillium’s website once released by the American Society of Hematology.

Trillium will host a conference call on Monday, December 7^th at 4:30PM EST.

International Dial-In Number: +1 236-389-2162
Conference ID: 3169183

Webcast link:
https://event.on24.com/wcc/r/2862177/A91BDB88D738527918C13E289B26CED7

A
bout Trillium Therapeutics

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.

For more information visit: www.trilliumtherapeutics.com 

Investor Relations
:

James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
[email protected]
www.trilliumtherapeutics.com  

Media Relations:

Mike Beyer
Sam Brown Inc.
312-961-2502
[email protected]

Simple, single-dose nasal spray
offers greater ease and comfort of administration
; 

positioning
AdCOVID as a
differentiated
vaccine
candidate
for adults and children

AdCOVID is capable of stimulating a
n additional and
specialized type of immunity –
local
nasal mucosal immunity –
believed to be
critical for preventing

further
transmission
of the virus

GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID. AdCOVID is designed to stimulate a broad immune response including both systemic immunity (neutralizing antibody) and local immunity (mucosal IgA and resident memory T cells) in the nasal cavity and respiratory tract.

“We’ve made exceptional progress advancing AdCOVID and are on track to begin a Phase 1 clinical study this year, with a data readout anticipated in the first quarter of 2021,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “While the progress being reported with current vaccines is very encouraging, many in the scientific and medical communities agree that there is continued need for next-generation vaccines that offer significant enhancements. AdCOVID has the potential to provide many benefits not offered by current vaccines, including simple intranasal administration (particularly well-suited for use in children), the ability to be transported at room temperature and conveniently stored in refrigerators for years, and the stimulation of nasal mucosal immunity with the potential to provide sterilizing immunity and block transmission of the SARS-CoV-2 virus. In addition to testing in adults, our IND included a preliminary proposal for evaluation of children as young as 2 years of age, and we look forward to further discussions around our pediatric program with the FDA in the near future.”  

“It’s not widely known or appreciated that nasal mucosal immunity may be essential in preventing the spread of the SARS-CoV-2 virus to other individuals by stopping replication and transmission of the virus at the site of infection – the nose and respiratory tract,” said Frances E. Lund, the Charles H. McCauley Professor and Chair for the University of Alabama at Birmingham, Department of Microbiology. “Several recent studies have shown that in the absence of mucosal immunity, the nasal cavity may become a reservoir for the coronavirus, particularly in children, potentially allowing for disease transmission even after an intramuscular vaccination. A vaccine that prevents transmission by children would allow them to return to school and their parents to return to work. We are excited to collaborate with Altimmune on the advancement of this important next-generation vaccine and look forward to seeing data from the upcoming clinical study.”

In a recent pre-IND meeting, the FDA agreed to the overall Phase 1 study design and patient population, as well as plans for manufacturing and product testing of AdCOVID. The FDA also confirmed that additional nonclinical studies were not required and that the toxicology data previously submitted and reviewed for Altimmune’s NasoShield™ and NasoVAX™ intranasal vaccine candidates support the clinical development of AdCOVID, with no additional toxicology studies required before initiation of the Phase 1 trial.

About AdCOVID

In recently published preclinical studies (www.biorxiv.org/content/10.1101/2020.10.10.331348v1) conducted in collaboration with the University of Alabama at Birmingham, potent serum neutralizing antibody and T cell responses were induced in mice in addition to a robust induction in mucosal immunity against the spike protein of the virus. Importantly, the mucosal immunity was characterized by IgA antibody and resident memory T cell responses in the respiratory tract, both are believed to be important in fighting infection.

Based on data from Altimmune’s other intranasal platform vaccines (NasoVAX^™ and NasoShield^™) AdCOVID is expected to have extended stability at room temperature allowing for cold chain-free shipment of the vaccine, where it can then be stored in common refrigerators found in community-based doctor’s offices and pharmacies for two years or more. The simple and convenient handling requirements may greatly increase the number of people willing to take the vaccine.

Altimmune anticipates commencing a Phase 1 safety and immunogenicity trial of AdCOVID in the fourth quarter of 2020 with a data readout in the first quarter of 2021.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

About UAB

Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is an internationally renowned research university and academic medical center, as well as Alabama’s largest employer, with some 23,000 employees, and has an annual economic impact exceeding $7 billion on the state. The pillars of UAB’s mission include education, research, innovation and economic development, community engagement, and patient care. Learn more at www.uab.edu.

Forward-Looking Statement

Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, the initiation and timing of the AdCOVID Phase 1 clinical trial in Q4 2020 and data readout in Q1 2021, the potential immunization effects of AdCOVID, the shipping and storage requirements for AdCOVID, the willingness of the general public to use AdCOVID, and the prospects for regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: potential impacts due to the COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; the Company’s ability to secure regulatory approval for its AdCOVID investigational new drug application submission to the U.S. Food and Drug Administration, the Company’s ability to manufacture clinical trial materials on the timelines anticipated; the Company’s ability to secure manufacturing approval from its SARS-CoV-2 cell licensor on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company’s business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2019 and quarterly report on Form 10-Q for the quarter ended March 31, 2020 filed with the SEC, which are available at www.sec.gov.

Investor Contacts:
Will Brown					Ashley R. Robinson
Chief Financial Officer					LifeSci Advisors, LLC
Phone: 240-654-1450					617-430-7577
[email protected]					[email protected]
Stacey Jurchison
Sr. Director, Investor Relations
Phone: 410-474-8200
[email protected]
Media Contact:
Warren Rizzi
Sard Verbinnen & Co.
Phone: 212-687-8080
[email protected]